Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 4 Plasma cell 2 Lymphoid 2 Thoracic 1 Other solid neoplasm 1 Gynecologic 1 Dermatologic 1 CNS 1

Conditions

Interventions

Nivolumab 114 Ipilimumab 114 pembrolizumab 108 aldesleukin 76 Cyclophosphamide 70 fludarabine phosphate 51 Interleukin-2 48 Temozolomide 41 Dacarbazine 36 trametinib 33 dabrafenib 30 Bevacizumab 30 sargramostim 29 Radiotherapy 29 incomplete Freund's adjuvant 27 fludarabine 27 Vemurafenib 25 Radiosurgery 25 Carboplatin 25 Paclitaxel 23 binimetinib 22 Biopsy 22 CTLA-4 Antigen 21 Peripheral Blood Stem Cell Transplantation 20 encorafenib 19 cemiplimab 19 atezolizumab 19 Mycophenolic Acid 19 HhAntag691 19 Aminolevulinic Acid 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × romiplostim × Dermatologic × Clear all

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡